Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Evotec | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Evotec

EVT Execute business up 35% in 1H16

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Evotec

2Q Revenues: €38.0 million (+14%)

2Q Earnings: €3.9 million (-73%)

YTD Revenues: €75.5 million (+37%)

YTD Earnings: €2.7 million (-80%)

Comments: Growth was driven by the EVT Execute business (up 35% to €79.8 million), the contribution of the Sanofi collaboration as well as milestone achievements. R&D expenses for the first half increased 6% to €9.0 million. Results include one-time effects with regards to the bargain purchase resulting from the acquisition of Evotec (France) SAS in 2015.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters